Clinical Trials Directory

Trials / Completed

CompletedNCT00946764

To Demonstrate the Relative Bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions

Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
48 (actual)
Sponsor
Sandoz · Industry
Sex
All
Age
19 Years – 54 Years
Healthy volunteers
Accepted

Summary

To demonstrate the relative bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg imipramine hydrochloride tablets in healthy adult volunteers under fasting conditions.

Conditions

Interventions

TypeNameDescription
DRUGImipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)
DRUGTofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)

Timeline

Start date
2005-07-01
Primary completion
2005-09-01
Completion
2005-09-01
First posted
2009-07-27
Last updated
2017-03-28

Source: ClinicalTrials.gov record NCT00946764. Inclusion in this directory is not an endorsement.

To Demonstrate the Relative Bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride (NCT00946764) · Clinical Trials Directory